Novocure

由Novocure 研发的肿瘤电场疗法（Tumor Treating Fields, TTFields）在Ⅲ期 PANOVA-3 研究中显示出可转化的生存获益——联用吉西他滨+白蛋白结合型紫杉醇的一线方案，试验报告中位总生存期为 16.2 个月（对照组约 14.2 个月，HR≈0.82，p≈0.039），且伴随疼痛进展延缓与两年生存率改善等次要终点...

#药闻简讯# PANOVA-3 是一项针对不可切除的局部晚期胰腺癌患者的关键性III期临床试验，旨在评估肿瘤电场治疗（TTFields）联合标准化疗的疗效与安全性。Novocure（主导）与再鼎医药（中国区合作）
比较了 GA 与 GA+gem/abraxane（GA）+肿瘤电场治疗（TTF）的效果，在局部晚期肺癌患者中，TTF 组...

$Novocure(NVCR)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001562180-25-005185  Size: 5 KB 网页链接

$Novocure(NVCR)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001562180-25-005188  Size: 5 KB 网页链接

TTF肿瘤电场。胰腺癌！！
$再鼎医药(09688)$ and NovoCure reported Phase 3 PANOVA-3 data at ASCO 2025 showing TTFields combined with chemotherapy significantly improved median overall survival and other key outcomes in pancreatic cancer versus chemotherapy alone.$Novocure(NV...

$Novocure(NVCR)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001562180-25-004561  Size: 7 KB 网页链接

$Novocure(NVCR)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001562180-25-004558  Size: 7 KB 网页链接

$Novocure(NVCR)$ 8-K Current report, items 5.02, 5.07, and 9.01 Accession Number: 0001645113-25-000011  Act: 34  Size: 282 KB 网页链接

$Novocure(NVCR)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001562180-25-004441  Size: 5 KB 网页链接

$Novocure(NVCR)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001645113-25-000023  Act: 33  Size: 145 KB 网页链接

$Novocure(NVCR)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001645113-25-000026  Act: 33  Size: 145 KB 网页链接

$Novocure(NVCR)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001645113-25-000027  Act: 33  Size: 145 KB 网页链接

$Novocure(NVCR)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001645113-25-000030  Act: 34  Size: 347 KB 网页链接

$Novocure(NVCR)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001562180-25-005572  Size: 7 KB 网页链接

$Novocure(NVCR)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001562180-25-004428  Size: 5 KB 网页链接

$Novocure(NVCR)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001562180-25-004440  Size: 5 KB 网页链接

$Novocure(NVCR)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001645113-25-000024  Act: 33  Size: 145 KB 网页链接

$Novocure(NVCR)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001562180-25-004553  Size: 5 KB 网页链接

$Novocure(NVCR)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001562180-25-004556  Size: 7 KB 网页链接

$Novocure(NVCR)$ 8-K Current report, items 7.01 and 9.01 Accession Number: 0001645113-25-000010  Act: 34  Size: 11 MB 网页链接